Loading...
XHKG
3759
Market cap7.49bUSD
Dec 05, Last price  
21.66HKD
1D
-0.09%
1Q
-7.28%
IPO
15.34%
Name

Pharmaron Beijing Co Ltd

Chart & Performance

D1W1MN
XHKG:3759 chart
P/E
29.54
P/S
4.32
EPS
0.67
Div Yield, %
1.09%
Shrs. gr., 5y
12.34%
Rev. gr., 5y
26.72%
Revenues
12.28b
+6.39%
790,440,0471,128,037,5581,634,238,6802,294,118,0662,908,123,0333,757,160,0865,133,596,7587,443,769,72410,266,288,17911,537,996,31412,275,774,875
Net income
1.79b
+12.01%
20,995,24073,846,442176,911,924230,857,087339,224,479547,191,4861,172,382,3871,661,028,5671,374,604,2241,601,096,0331,793,350,814
CFO
2.58b
-6.42%
12,134,600216,939,062235,767,733552,215,324737,258,351938,586,3211,648,609,9572,058,043,8302,142,816,4162,753,538,9342,576,656,397
Dividend
Jun 27, 20240.23614 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
IPO date
Jan 28, 2019
Employees
19,733
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT